Past Issues

Actos (pioglitazone hydrochloride), used against diabetes to prevent complications, was approved in 1999.

Our analyses concluded the following: that there is no evidence of complications being prevented, and that cardiotoxicity and carcinogenesis have been reported.

Based on this, we submitted a written request to the Ministry of Health, Labour and Welfare and pharmaceutical industries to suspend and recall the medicine in January 2001, and conducted a survey with sending out questionnaires to 512 hospitals in 2003.

• Drugs
• Systems